Market Cap: $108 Million Cash: $72 Million Price: $2.40 Shares Out: 45.3 Million Upcoming Major Milestones Zalviso Phase 3 Results in July 2017 DSUVIA PDUFA Date October 12, 2017 Zalsviso NDA Resubmission in Q4 2017 DSUVIA CHMP Opinion in 1H 2018 (EU Approval ) Presentation June 2017 http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjczNjExfENoaWxkSUQ9MzgxNTY1fFR5cGU9MQ==&t=1 Jefferies Sees Strong Upside in AcelRx Pharmaceuticals’ Shares and Set a $7 Price Target https://finance.yahoo.com/news/jefferies-sees-strong-upside-acelrx-145225845.html Biotech Catalyst Play: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)... https://insiderfinancial.com/biotech-catalyst-play-acelrx-pharmaceuticals-inc-nasdaqacrx While Zalviso is our near-term catalyst, the DSUVIA decision probably holds more weight from a valuation perspective. Why? Because peak sales for this one are estimated at a little over $1.1 billion in the US alone. If FDA gives a green light for commercialization to the asset, therefore, the company could have a blockbuster drug on its hands. Combine that with the close to $400 million in revenues potential from Zalviso, and AcelRx could very justifiably become a multibillion-dollar biotech company before the end of the decade.